trial · primary record
Seltorexant
Depressive Disorder, Major
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 600 |
| Primary completion | 2029-05-03 |
| Primary endpoint | Double Blind (DB) Treatment Phase: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score in Participants with Major Depressive Disorder with Moderate-to-Severe Insomnia Symptoms (MDDIS) |
| Registry ID | NCT07573176 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:26.580Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07573176
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Seltorexant · compound